San Diego-centered Viking Therapeutics marked by itself as a serious competitor during the weight loss drug marketplace in February following revealing promising facts from the mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection As well as in March th